Drug-resistant infections such as MRSA are widespread among children in Oceania, with major gaps in access and approved ...

Theriva received a $300,000 upfront payment at signing and is eligible for up to $38M in development, regulatory, and sales milestones along ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial ...

Theriva received a $300,000 upfront payment at signing and is eligible for up to $38M in development, regulatory, and sales milestones along with tiered single-digit royalties on net product sales - - ...

Life-saving antibiotics that could treat severe infections in babies and children aren't accessible due to a lack of data around safety and dosage, new research shows. Two wide sweeping reviews, led ...

Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in an invited session at the 41st Asia-Pacific Academy of ...

Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in an invited session at the 41st Asia-Pacific Academy of Opht ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, ...

Bacteria have evolved to adapt to all of Earth's most extreme conditions, from scorching heat to temperatures well below zero. Ice caves are just one of the environments hosting a variety of ...

Bacteria have evolved to adapt to all of Earth's most extreme conditions, from scorching heat to temperatures well below zero ...

The discovery of an antibiotic-resistant microbe locked in Romanian cave ice highlights both the risks of a warming world and ...